38
INDUSTRY NEWS
INDUSTRY
NEWS
Kerstin Kirchhübel, Christian Kirchhübel, Rainer Kirchhübel, Rita Kirchhübel and Matthias Kirchhübel celebrating 125 years of Oculus
125 years of Oculus Keep learning. Whenever, wherever.
OCULUS Optikgeräte GmbH celebrated 125 years with a special meeting in its headquarters in Wetzlar, Germany. The company, which produces devices across the ophthalmic spectrum, from trial lenses and visual field tests to topography and tonography, has been based in the “optic town” of Wetzlar since 1947. The company has created several products that have had a high impact on the world of ophthalmology. In 1985 it presented the SDI BIOM system, a non-contact wide-angle viewing system for vitreoretinal surgery, a system that is still in use today. In 2002 the company announced the Pentacam, the world’s first rotating Scheimpflug camera. It remains one of the company’s flagship products, alongside the Pentacam HR and AXL models. A tour of the Oculus facility showed the full scope of its manufacturing processes, from robotic operations to handheld burring and assembly. https://www.oculus.de/
MERGER DISCUSSIONS
Learn online in your own time, with self-paced and assessed ESCRS iLearn courses on: ∙ Cataract Surgery ∙ Cornea
∙ Refractive Surgery ∙ Visual Optics
Trainers: use the task list to assign courses for trainees and monitor their progress.
Learn more at https://elearning.escrs.org EUROTIMES | MARCH 2020
Quantel Medical and the Lumibird group has initiated merger discussions with Ellex, Adelaide, Australia. “The future success of both companies depends on sharing R&D capability and manufacturing structures, on strengthening our approach to clinical research in order to meet the current and future needs of the ophthalmologists,” said Jean-Marc Gendre, Quantel Medical’s CEO. “The vision is to become the world leader in ophthalmic ultrasound and laser technology solution to diagnose and treat eye diseases” said Marc Le Flohic, Lumibird group’s CEO. https://www.quantelmedical.com/
NEW CORNEA HEALTH FRANCHISE Glaukos Corporation has completed its acquisition of Avedro, Inc. “Avedro will serve as the cornerstone of our new corneal health franchise,” said Thomas Burns, Glaukos president and CEO. “This pairs two highly complementary, hybrid pharma and device organisations, combining Avedro’s novel bio-activated pharmaceutical solutions and R&D capabilities with Glaukos’ global commercial scale, proven marketbuilding and shared reimbursement expertise, and extensive clinical and regulatory infrastructure.” https:// www.glaukos.com/
